HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Steven A Gilbert Selected Research

PF-06700841

12/2020TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Steven A Gilbert Research Topics

Disease

1Inflammation (Inflammations)
12/2021
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
12/2021
1Rheumatic Diseases (Rheumatism)
12/2021
1Experimental Arthritis
12/2021
1Rheumatoid Arthritis
12/2021
1Psoriasis (Pustulosis Palmaris et Plantaris)
12/2020
1Hemophilia A (Haemophilia)
01/2007

Drug/Important Bio-Agent (IBA)

11- (((2S,3S,4S)- 3- ethyl- 4- fluoro- 5- oxopyrrolidin- 2- yl)methoxy)- 7- methoxyisoquinoline- 6- carboxamideIBA
12/2021
1LigandsIBA
12/2021
1Phosphotransferases (Kinase)IBA
12/2021
1Toll-Like Receptors (Toll-Like Receptor)IBA
12/2021
1Interleukin-1 Receptor-Associated KinasesIBA
12/2021
1pristane (pristan)IBA
12/2021
1Anti-Citrullinated Protein AntibodiesIBA
12/2021
1Antigen-Antibody Complex (Immune Complex)IBA
12/2021
1PF-06700841IBA
12/2020
1anti-inhibitor coagulant complexIBA
01/2007
1AntibodiesIBA
01/2007
1Factor VIII (Coagulation Factor VIII)IBA
01/2007
1recombinant FVIIa (rFVIIa)FDA Link
01/2007